GHRP-6 vs Ipamorelin
A side-by-side research comparison of GHRP-6 and Ipamorelin across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | GHRP-6 | Ipamorelin |
|---|---|---|
| Full name | Growth Hormone Releasing Peptide-6 | Ipamorelin (Selective GH Secretagogue) |
| Category | Growth Hormone | Growth Hormone |
| Status | Research compound | Research compound |
| Mechanism | Activates GHSR-1a on pituitary for GH release and hypothalamic neurons for appetite. Triggers gastric motility and ghrelin-like reward signaling. | Selectively activates GHSR on pituitary somatotrophs. Unlike GHRP-6 and hexarelin, does not significantly activate ACTH or prolactin-releasing pathways. |
| Molecular weight | 873 Da | 711.9 Da |
| Half-life | 2-3 hours | 2 hours |
| Bioavailability | High (SubQ) | High (SubQ) |
| Typical dose | 100-300 mcg | 100-300 mcg |
| Frequency | 2-3x daily | 1-3x daily |
| Route | Subcutaneous | Subcutaneous injection |
GHRP-6 reported benefits
- Strong GH release
- Powerful appetite stimulation
- Gastric motility improvement
- Recovery enhancement
- Gut healing support
Ipamorelin reported benefits
- Clean GH release
- No cortisol or prolactin increase
- Improved sleep
- Fat loss
- Joint support
- Anti-aging benefits
Related comparisons
Research and educational reference only. Not medical advice.